ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

@article{Kempf1995ABT538IA,
  title={ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.},
  author={Dale J. Kempf and Kennan C. Marsh and Jon F. Denissen and Edith J McDonald and Sudthida Vasavanonda and Charles A Flentge and Brian E Green and Leonardo Fino and Chan Ho Park and Xianqi Kong},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1995},
  volume={92 7},
  pages={2484-8}
}
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of symmetry-based inhibitors of the human immunodeficiency virus (HIV) protease led to the discovery of ABT-538, a promising experimental drug for the therapeutic intervention in acquired immunodeficiency syndrome (AIDS). ABT-538 exhibited potent in vitro activity against laboratory and clinical strains of HIV-1 [50% effective concentration (EC50) = 0.022-0.13 microM] and HIV… CONTINUE READING

From This Paper

Topics from this paper.
103 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 103 extracted citations

Similar Papers

Loading similar papers…